<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60. The etiopathogenesis of the disease is multifactorial, the key factors being genetic predisposition combined with immunological disorders, environmental factors and skin barrier damage. There are several clinical variants of the disease. The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17. Topical agents are used for the treatment of the mild form, and the systemic conventional therapy is used for the treatment of moderate to severe forms of the disease. In cases where’s no response, or intolerance or contraindications are present, new targeted medications are to be administered. Development in the field of immunogenetics of psoriasis leads to personalized medicine.</p></abstract>

Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60. The etiopathogenesis of the disease is multifactorial, the key factors being genetic predisposition combined with immunological disorders, environmental factors and skin barrier damage. There are several clinical variants of the disease. The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17. Topical agents are used for the treatment of the mild form, and the systemic conventional therapy is used for the treatment of moderate to severe forms of the disease. In cases where’s no response, or intolerance or contraindications are present, new targeted medications are to be administered. Development in the field of immunogenetics of psoriasis leads to personalized medicine.

A modern approach to the treatment of plaque psoriasis

Department of Dermatology and Venereology

Department of Infectious Diseases and Dermatovenereology

Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Botany

Faculty of Pharmacy and Biochemistry, Department of Pharmacology

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"A modern approach to the treatment of plaque psoriasis"}

Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the...

A modern approach to the treatment of plaque psoriasis

Publicado en línea: 21 oct 2019

Páginas: 511 - 523

Aceptado: 23 jun 2019

DOI: https://doi.org/10.2478/acph-2019-0047

Palabras clave
psoriasis, topical treatment, conventional systemic therapy, small molecules, biologicals

© 2019 Daniela Ledić Drvar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

A modern approach to the treatment of plaque psoriasis

Publicado en línea: 21 oct 2019

Páginas: 511 - 523

Aceptado: 23 jun 2019

DOI: https://doi.org/10.2478/acph-2019-0047

Palabras clavepsoriasis, topical treatment, conventional systemic therapy, small molecules, biologicals

© 2019 Daniela Ledić Drvar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
psoriasis, topical treatment, conventional systemic therapy, small molecules, biologicals